Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Would the recurrence while already on the checkpoint inhibitor sway you from offering durvalumab?
Answer from: Medical Oncologist at Academic Institution
No, I would not
Sign in or Register to read more